Three-Arm Noninferiority Trials with a Prespecified Margin for Inference of the Difference in the Proportions of Binary Endpoints

被引:12
作者
Hida, Eisuke [1 ]
Tango, Toshiro [2 ]
机构
[1] Natl Inst Publ Hlth, Dept Technol Assessment & Biostat, Wako, Saitama 3510197, Japan
[2] Ctr Med Stat, Tokyo, Japan
关键词
Assay sensitivity; Binary endpoint; Optimal allocation; Prespecified noninferiority margin; Three-arm noninferiority; NON-INFERIORITY TRIALS; GOLD STANDARD DESIGN; PLACEBO;
D O I
10.1080/10543406.2013.789893
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The design of a three-arm trial including the experimental treatment, an active reference treatment, and a placebo is recommended as a useful approach to the assessment of noninferiority of the experimental treatment. The inclusion of the placebo arm enables the assessment of assay sensitivity and internal validation, in addition to testing the noninferiority of the experimental treatment to the reference. Generally, the acceptable noninferiority margin has been defined as the maximum clinically irrelevant difference between treatments in many two-arm noninferiority trials. However, many articles have considered a design in which the noninferiority margin is relatively defined as a prespecified fraction f of the unknown effect size of the reference treatment. Therefore, these methods cannot be applied to cases where the margin is defined as a prespecified difference between treatments. In this article, we propose score-based statistical procedures for a three-arm noninferiority trial with a prespecified margin for inference of the difference in the proportions of binary endpoints. In addition, we derive the approximate sample size and optimal allocation to minimize the total sample size and that of the placebo arm. A randomized controlled trial on major depressive disorder based on the difference in the proportions of remission is used to demonstrate our proposed method.
引用
收藏
页码:774 / 789
页数:16
相关论文
共 25 条
  • [11] Simultaneous confidence interval for assessing non-inferiority with assay sensitivity in a three-arm trial with binary endpoints
    Tang, Niansheng
    Yu, Bin
    PHARMACEUTICAL STATISTICS, 2020, 19 (05) : 518 - 531
  • [12] Group sequential designs for three-arm 'gold standard' non-inferiority trials with fixed margin
    Schloemer, Patrick
    Brannath, Werner
    STATISTICS IN MEDICINE, 2013, 32 (28) : 4875 - 4889
  • [13] A studentized permutation test for three-arm trials in the 'gold standard' design
    Muetze, Tobias
    Konietschke, Frank
    Munk, Axel
    Friede, Tim
    STATISTICS IN MEDICINE, 2017, 36 (06) : 883 - 898
  • [14] New approaches for testing non-inferiority for three-arm trials with Poisson distributed outcomes
    Ghosh, Samiran
    Paul, Erina
    Chowdhury, Shrabanti
    Tiwari, Ram C.
    BIOSTATISTICS, 2022, 23 (01) : 136 - 156
  • [15] Blinded sample size re-estimation in three-arm trials with "gold standard' design
    Muetze, Tobias
    Friede, Tim
    STATISTICS IN MEDICINE, 2017, 36 (23) : 3636 - 3653
  • [16] Confidence Intervals for Assessing Non-Inferiority with Assay Sensitivity in a Three-Arm Trial with Normally Distributed Endpoints
    Tang, Niansheng
    Liang, Fan
    MATHEMATICS, 2022, 10 (02)
  • [17] Bayesian approach for assessing non-inferiority in a three-arm trial with pre-specified margin
    Ghosh, Samiran
    Ghosh, Santu
    Tiwari, Ram C.
    STATISTICS IN MEDICINE, 2016, 35 (05) : 695 - 708
  • [18] Semiparametric Bayesian approach to assess non-inferiority with assay sensitivity in a three-arm trial with normally distributed endpoints
    Tang, Niansheng
    Liang, Fan
    Jiang, Depeng
    COMPUTATIONAL STATISTICS, 2024, 39 (04) : 2157 - 2181
  • [19] Semiparametric Bayesian approach to assess non-inferiority with assay sensitivity in a three-arm trial with normally distributed endpoints
    Niansheng Tang
    Fan Liang
    Depeng Jiang
    Computational Statistics, 2024, 39 : 2157 - 2181
  • [20] Bayesian Approach for Assessing Non-Inferiority in Three-Arm Trials for Risk Ratio and Odds Ratio
    Chowdhury, Shrabanti
    Tiwari, Ram C.
    Ghosh, Samiran
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2019, 11 (01): : 34 - 43